Preliminary study of the safety and immunogenicity of the attenuated VD47/25 strain of camelpoxvirus

Abstract

The safety and immunogenicity of the attenuated VD_47/25 strain of camelpoxvirus were tested on 30 camel calves in Mauritania. Post-inoculation clinical symptoms were absent during the 40 days of observation. Serum samples collected during this period showed low levels of neutralizing antibodies (1/4-1/16). In vivo titration of a virulent strain of camelpoxvirus in vaccinated camels and control animals enabled the calculation of the PD₅₀ (50 % protective dose) which contained the equivalent of 10^3.7 TCID₅₀ (50 % cell culture infective dose). Other studies are still required to determine the dose of this vaccine needed to protect 95% of vaccinated animals.